ECTMIH 2019

16-20 September 2019
Liverpool, UK

  • DND– one symposium on cutaneous leishmaniasis and one on mycetoma
  • Nathalie Strub-Wourgaft, NTD Director – panel discussion on the future of research and development, satellite symposium on sleeping sickness

Chagas disease: the time is now to end 110 years of neglect

Rio de Janeiro – 11 April 2019
The people affected by Chagas disease will claim this 14th of April as World Chagas Day in the hope of increasing global awareness, building on the progress already made against this disease, which has been neglected for more than a century
The International Federation of Associations of People Affected by Chagas disease (FINDECHAGAS) has launched an online petition through the platform change.org in support of the official declaration of April 14th as their World Day. This proposal will be tabled at the 72nd World Health Assembly, to be held in Geneva at the end of May 2019. The particular date has been chosen because on that same day, 110 years ago, the Brazilian doctor Carlos Chagas confirmed the first case of the disease in a child, called Berenice Soares.

Chagas disease – Breaking the Silence

22 May 2019
Geneva, Switzerland

  • DNDi co-organizing – panel discussion to discuss the major hurdles preventing access to quality care and treatment and how the global health community can best move forwards to eradicate Chagas disease

Le fexinidazole, premier traitement entièrement par voie orale contre la maladie du sommeil, approuvé en République Démocratique du Congo

Paris/Genève, 30 Janvier 2019

La République Démocratique du Congo (RDC) a délivré une autorisation de mise sur le marché au fexinidazole pour le traitement de la trypanosomiase humaine africaine (THA) ou maladie du sommeil causée par le parasite Trypanosoma brucei gambiense. Cette approbation ouvre la voie à la distribution du  fexinidazole, cette année, dans les pays où la maladie du sommeil est endémique, sachant qu’une autre soumission réglementaire est également prévue en Ouganda.

アフリカ睡眠病初の経口治療薬フェキシニダゾールがコンゴ民主共和国において承認を取得

[2019年1月30日 パリ/ジュネーブ]

ガンビア・トリパノソーマ (Trypanosoma brucei gambiense) によるヒト・アフリカ・トリパノソーマ症 (HAT、別名アフリカ睡眠病) の治療薬として、コンゴ民主共和国 (DRC) においてフェキシニダゾールの申請が承認されました。これにより、ウガンダで予定されている申請とともに、今年フェキシニダゾールを流行国において普及させる道が開かれました。

DNDi welcomes the findings of the 2018 G-FINDER report

23 January 2019
Geneva, Switzerland
The annual G-FINDER report provides policy-makers, donors, researchers, and industry with a comprehensive analysis of global investment into R&D of new products to prevent, diagnose, control, or cure neglected diseases in developing countries. It gives an up-to-date analysis of how R&D investments are being allocated across 33 neglected diseases, and product types, funding trends over time, and where the potential gaps lie.